Comment from Pharmaceutical Research and Manufacturers of America (PhRMA)

Summary: PhRMA, representing the biopharmaceutical research industry, supports the FDA's Rare Disease Innovation Hub and proposes specific topics for future workshops. They advocate for discussing innovative statistical approaches, predictive and mechanistic modeling, and Bayesian analyses to better establish associations between biomarkers and clinical outcomes in rare disease drug development.